妇产科

订阅

MedSci主页 / 所有栏目 / 妇产科

Arch Gynecol Obstet：dienogest长期治疗子宫内膜异位症的效果

2019-06-15 不详 网络

关注

子宫内膜异位症是一种使人衰弱的疾病，复发率高，需要长期治疗。当出现第一个症状时和手术后根据经验使用孕激素如地诺孕素以减少复发。这项基于实践的回顾性研究评估了dienogest治疗子宫内膜异位症至少60个月的妇女的疗效和安全性。37名患有腹腔镜诊断的子宫内膜异位症的女性（年龄39±8岁）每天口服一次地诺孕素2 mg。子宫内膜异位症相关性骨盆疼痛（EAPP）在基线和每12个月在0-100mm视觉模拟量

子宫内膜异位症是一种使人衰弱的疾病，复发率高，需要长期治疗。当出现第一个症状时和手术后根据经验使用孕激素如地诺孕素以减少复发。这项基于实践的回顾性研究评估了dienogest治疗子宫内膜异位症至少60个月的妇女的疗效和安全性。

37名患有腹腔镜诊断的子宫内膜异位症的女性（年龄39±8岁）每天口服一次地诺孕素2 mg。子宫内膜异位症相关性骨盆疼痛（EAPP）在基线和每12个月在0-100mm视觉模拟量表上测量。在15名妇女的亚组中研究了脂质和肝脏代谢，止血和激素参数的实验室测量。记录包括出血紊乱和抑郁症状在内的不良事件。

在22名女性中，dienogest在腹腔镜检查后开始;在12,24,36,88和60个月的地诺孕酮治疗后，EAPP评分中位数分别为术前70 mm和10,10,20,20和20 mm。另有15名妇女在未事先手术的情况下开始使用dienogest在12,24,36,48和60个月后，中位EAPP评分分别为80 mm预处理和20,20,30,30和30 mm。所有实验室参数均保持在正常范围内。 60个月后平均血清雌二醇为28±12pg / ml。七名女性经历了发现事件，四名女性出现了情绪低落的阶段，这些都可以在临床上进行管理。

在子宫内膜异位症患者中，每日一次使用地诺孕素2 mg长期（60个月）治疗可有效降低EAPP并避免术后疼痛复发。 Dienogest具有良好的耐受性，临床管理不良反应。

原始出处：

Römer T. Long-term treatment of endometriosis with dienogest: retrospective analysis of efficacy and safety in clinical practice. Arch Gynecol Obstet. 2018 Oct;298(4):747-753. doi: 10.1007/s00404-018-4864-8. Epub 2018 Aug 3.


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2055552, encodeId=23a120555521a, content=<a href='/topic/show?id=4ebf9e016c6' target=_blank style='color:#2F92EE;'>#长期治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97016, encryptionId=4ebf9e016c6, topicName=长期治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Dec 23 20:14:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665653, encodeId=734b166565362, content=<a href='/topic/show?id=685445152f6' target=_blank style='color:#2F92EE;'>#子宫内膜异位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45152, encryptionId=685445152f6, topicName=子宫内膜异位)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de125981980, createdName=12498f17m74暂无昵称, createdTime=Sun Dec 22 03:14:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708526, encodeId=bafa1e08526be, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Fri May 08 22:14:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051395, encodeId=5aa220513958c, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat May 09 21:14:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011410, encodeId=f7b92011410f0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Oct 03 07:14:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044100, encodeId=2a08204410090, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jul 24 19:14:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956562, encodeId=46c51956562ee, content=<a href='/topic/show?id=9559e976b0' target=_blank style='color:#2F92EE;'>#GES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7976, encryptionId=9559e976b0, topicName=GES)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sat Oct 05 03:14:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569661, encodeId=f0501569661b5, content=<a href='/topic/show?id=961b5945dd' target=_blank style='color:#2F92EE;'>#DIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5945, encryptionId=961b5945dd, topicName=DIE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76015553894, createdName=lg.zhao, createdTime=Mon Jun 17 06:14:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046845, encodeId=f750104684597, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jun 15 18:14:00 CST 2019, time=2019-06-15, status=1, ipAttribution=)]
    2019-12-23 bugit

    #长期治疗#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2055552, encodeId=23a120555521a, content=<a href='/topic/show?id=4ebf9e016c6' target=_blank style='color:#2F92EE;'>#长期治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97016, encryptionId=4ebf9e016c6, topicName=长期治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Dec 23 20:14:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665653, encodeId=734b166565362, content=<a href='/topic/show?id=685445152f6' target=_blank style='color:#2F92EE;'>#子宫内膜异位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45152, encryptionId=685445152f6, topicName=子宫内膜异位)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de125981980, createdName=12498f17m74暂无昵称, createdTime=Sun Dec 22 03:14:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708526, encodeId=bafa1e08526be, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Fri May 08 22:14:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051395, encodeId=5aa220513958c, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat May 09 21:14:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011410, encodeId=f7b92011410f0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Oct 03 07:14:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044100, encodeId=2a08204410090, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jul 24 19:14:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956562, encodeId=46c51956562ee, content=<a href='/topic/show?id=9559e976b0' target=_blank style='color:#2F92EE;'>#GES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7976, encryptionId=9559e976b0, topicName=GES)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sat Oct 05 03:14:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569661, encodeId=f0501569661b5, content=<a href='/topic/show?id=961b5945dd' target=_blank style='color:#2F92EE;'>#DIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5945, encryptionId=961b5945dd, topicName=DIE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76015553894, createdName=lg.zhao, createdTime=Mon Jun 17 06:14:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046845, encodeId=f750104684597, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jun 15 18:14:00 CST 2019, time=2019-06-15, status=1, ipAttribution=)]
    2019-12-22 12498f17m74暂无昵称

    #子宫内膜异位#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2055552, encodeId=23a120555521a, content=<a href='/topic/show?id=4ebf9e016c6' target=_blank style='color:#2F92EE;'>#长期治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97016, encryptionId=4ebf9e016c6, topicName=长期治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Dec 23 20:14:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665653, encodeId=734b166565362, content=<a href='/topic/show?id=685445152f6' target=_blank style='color:#2F92EE;'>#子宫内膜异位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45152, encryptionId=685445152f6, topicName=子宫内膜异位)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de125981980, createdName=12498f17m74暂无昵称, createdTime=Sun Dec 22 03:14:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708526, encodeId=bafa1e08526be, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Fri May 08 22:14:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051395, encodeId=5aa220513958c, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat May 09 21:14:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011410, encodeId=f7b92011410f0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Oct 03 07:14:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044100, encodeId=2a08204410090, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jul 24 19:14:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956562, encodeId=46c51956562ee, content=<a href='/topic/show?id=9559e976b0' target=_blank style='color:#2F92EE;'>#GES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7976, encryptionId=9559e976b0, topicName=GES)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sat Oct 05 03:14:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569661, encodeId=f0501569661b5, content=<a href='/topic/show?id=961b5945dd' target=_blank style='color:#2F92EE;'>#DIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5945, encryptionId=961b5945dd, topicName=DIE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76015553894, createdName=lg.zhao, createdTime=Mon Jun 17 06:14:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046845, encodeId=f750104684597, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jun 15 18:14:00 CST 2019, time=2019-06-15, status=1, ipAttribution=)]
    2020-05-08 12498974m61暂无昵称

    #内膜#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2055552, encodeId=23a120555521a, content=<a href='/topic/show?id=4ebf9e016c6' target=_blank style='color:#2F92EE;'>#长期治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97016, encryptionId=4ebf9e016c6, topicName=长期治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Dec 23 20:14:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665653, encodeId=734b166565362, content=<a href='/topic/show?id=685445152f6' target=_blank style='color:#2F92EE;'>#子宫内膜异位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45152, encryptionId=685445152f6, topicName=子宫内膜异位)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de125981980, createdName=12498f17m74暂无昵称, createdTime=Sun Dec 22 03:14:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708526, encodeId=bafa1e08526be, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Fri May 08 22:14:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051395, encodeId=5aa220513958c, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat May 09 21:14:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011410, encodeId=f7b92011410f0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Oct 03 07:14:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044100, encodeId=2a08204410090, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jul 24 19:14:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956562, encodeId=46c51956562ee, content=<a href='/topic/show?id=9559e976b0' target=_blank style='color:#2F92EE;'>#GES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7976, encryptionId=9559e976b0, topicName=GES)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sat Oct 05 03:14:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569661, encodeId=f0501569661b5, content=<a href='/topic/show?id=961b5945dd' target=_blank style='color:#2F92EE;'>#DIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5945, encryptionId=961b5945dd, topicName=DIE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76015553894, createdName=lg.zhao, createdTime=Mon Jun 17 06:14:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046845, encodeId=f750104684597, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jun 15 18:14:00 CST 2019, time=2019-06-15, status=1, ipAttribution=)]
    2020-05-09 xiangyuzhou971

    #EST#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2055552, encodeId=23a120555521a, content=<a href='/topic/show?id=4ebf9e016c6' target=_blank style='color:#2F92EE;'>#长期治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97016, encryptionId=4ebf9e016c6, topicName=长期治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Dec 23 20:14:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665653, encodeId=734b166565362, content=<a href='/topic/show?id=685445152f6' target=_blank style='color:#2F92EE;'>#子宫内膜异位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45152, encryptionId=685445152f6, topicName=子宫内膜异位)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de125981980, createdName=12498f17m74暂无昵称, createdTime=Sun Dec 22 03:14:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708526, encodeId=bafa1e08526be, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Fri May 08 22:14:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051395, encodeId=5aa220513958c, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat May 09 21:14:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011410, encodeId=f7b92011410f0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Oct 03 07:14:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044100, encodeId=2a08204410090, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jul 24 19:14:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956562, encodeId=46c51956562ee, content=<a href='/topic/show?id=9559e976b0' target=_blank style='color:#2F92EE;'>#GES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7976, encryptionId=9559e976b0, topicName=GES)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sat Oct 05 03:14:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569661, encodeId=f0501569661b5, content=<a href='/topic/show?id=961b5945dd' target=_blank style='color:#2F92EE;'>#DIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5945, encryptionId=961b5945dd, topicName=DIE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76015553894, createdName=lg.zhao, createdTime=Mon Jun 17 06:14:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046845, encodeId=f750104684597, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jun 15 18:14:00 CST 2019, time=2019-06-15, status=1, ipAttribution=)]
    2019-10-03 yhy100200

    #TET#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2055552, encodeId=23a120555521a, content=<a href='/topic/show?id=4ebf9e016c6' target=_blank style='color:#2F92EE;'>#长期治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97016, encryptionId=4ebf9e016c6, topicName=长期治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Dec 23 20:14:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665653, encodeId=734b166565362, content=<a href='/topic/show?id=685445152f6' target=_blank style='color:#2F92EE;'>#子宫内膜异位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45152, encryptionId=685445152f6, topicName=子宫内膜异位)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de125981980, createdName=12498f17m74暂无昵称, createdTime=Sun Dec 22 03:14:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708526, encodeId=bafa1e08526be, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Fri May 08 22:14:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051395, encodeId=5aa220513958c, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat May 09 21:14:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011410, encodeId=f7b92011410f0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Oct 03 07:14:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044100, encodeId=2a08204410090, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jul 24 19:14:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956562, encodeId=46c51956562ee, content=<a href='/topic/show?id=9559e976b0' target=_blank style='color:#2F92EE;'>#GES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7976, encryptionId=9559e976b0, topicName=GES)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sat Oct 05 03:14:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569661, encodeId=f0501569661b5, content=<a href='/topic/show?id=961b5945dd' target=_blank style='color:#2F92EE;'>#DIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5945, encryptionId=961b5945dd, topicName=DIE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76015553894, createdName=lg.zhao, createdTime=Mon Jun 17 06:14:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046845, encodeId=f750104684597, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jun 15 18:14:00 CST 2019, time=2019-06-15, status=1, ipAttribution=)]
    2019-07-24 1249842em09(暂无昵称)

    #NEC#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2055552, encodeId=23a120555521a, content=<a href='/topic/show?id=4ebf9e016c6' target=_blank style='color:#2F92EE;'>#长期治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97016, encryptionId=4ebf9e016c6, topicName=长期治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Dec 23 20:14:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665653, encodeId=734b166565362, content=<a href='/topic/show?id=685445152f6' target=_blank style='color:#2F92EE;'>#子宫内膜异位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45152, encryptionId=685445152f6, topicName=子宫内膜异位)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de125981980, createdName=12498f17m74暂无昵称, createdTime=Sun Dec 22 03:14:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708526, encodeId=bafa1e08526be, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Fri May 08 22:14:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051395, encodeId=5aa220513958c, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat May 09 21:14:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011410, encodeId=f7b92011410f0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Oct 03 07:14:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044100, encodeId=2a08204410090, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jul 24 19:14:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956562, encodeId=46c51956562ee, content=<a href='/topic/show?id=9559e976b0' target=_blank style='color:#2F92EE;'>#GES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7976, encryptionId=9559e976b0, topicName=GES)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sat Oct 05 03:14:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569661, encodeId=f0501569661b5, content=<a href='/topic/show?id=961b5945dd' target=_blank style='color:#2F92EE;'>#DIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5945, encryptionId=961b5945dd, topicName=DIE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76015553894, createdName=lg.zhao, createdTime=Mon Jun 17 06:14:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046845, encodeId=f750104684597, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jun 15 18:14:00 CST 2019, time=2019-06-15, status=1, ipAttribution=)]
    2019-10-05 h.y200607_23674418

    #GES#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2055552, encodeId=23a120555521a, content=<a href='/topic/show?id=4ebf9e016c6' target=_blank style='color:#2F92EE;'>#长期治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97016, encryptionId=4ebf9e016c6, topicName=长期治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Dec 23 20:14:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665653, encodeId=734b166565362, content=<a href='/topic/show?id=685445152f6' target=_blank style='color:#2F92EE;'>#子宫内膜异位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45152, encryptionId=685445152f6, topicName=子宫内膜异位)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de125981980, createdName=12498f17m74暂无昵称, createdTime=Sun Dec 22 03:14:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708526, encodeId=bafa1e08526be, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Fri May 08 22:14:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051395, encodeId=5aa220513958c, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat May 09 21:14:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011410, encodeId=f7b92011410f0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Oct 03 07:14:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044100, encodeId=2a08204410090, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jul 24 19:14:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956562, encodeId=46c51956562ee, content=<a href='/topic/show?id=9559e976b0' target=_blank style='color:#2F92EE;'>#GES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7976, encryptionId=9559e976b0, topicName=GES)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sat Oct 05 03:14:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569661, encodeId=f0501569661b5, content=<a href='/topic/show?id=961b5945dd' target=_blank style='color:#2F92EE;'>#DIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5945, encryptionId=961b5945dd, topicName=DIE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76015553894, createdName=lg.zhao, createdTime=Mon Jun 17 06:14:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046845, encodeId=f750104684597, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jun 15 18:14:00 CST 2019, time=2019-06-15, status=1, ipAttribution=)]
    2019-06-17 lg.zhao

    #DIE#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2055552, encodeId=23a120555521a, content=<a href='/topic/show?id=4ebf9e016c6' target=_blank style='color:#2F92EE;'>#长期治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97016, encryptionId=4ebf9e016c6, topicName=长期治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Dec 23 20:14:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665653, encodeId=734b166565362, content=<a href='/topic/show?id=685445152f6' target=_blank style='color:#2F92EE;'>#子宫内膜异位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45152, encryptionId=685445152f6, topicName=子宫内膜异位)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de125981980, createdName=12498f17m74暂无昵称, createdTime=Sun Dec 22 03:14:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708526, encodeId=bafa1e08526be, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Fri May 08 22:14:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051395, encodeId=5aa220513958c, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat May 09 21:14:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011410, encodeId=f7b92011410f0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Oct 03 07:14:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044100, encodeId=2a08204410090, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jul 24 19:14:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956562, encodeId=46c51956562ee, content=<a href='/topic/show?id=9559e976b0' target=_blank style='color:#2F92EE;'>#GES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7976, encryptionId=9559e976b0, topicName=GES)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sat Oct 05 03:14:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569661, encodeId=f0501569661b5, content=<a href='/topic/show?id=961b5945dd' target=_blank style='color:#2F92EE;'>#DIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5945, encryptionId=961b5945dd, topicName=DIE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76015553894, createdName=lg.zhao, createdTime=Mon Jun 17 06:14:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046845, encodeId=f750104684597, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jun 15 18:14:00 CST 2019, time=2019-06-15, status=1, ipAttribution=)]
    2019-06-15 CHANGE

    疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的

    0